This thesis examines the sequence of events from melanoma diagnosis to disease progression. Different diagnostic aids to facilitate early detection are evaluated. Characteristics and prognosis of melanomas that arise as new lesions compared to those that arise within a pre-existing mole are investigated. Patient, pathological and mutational factors related to the pathways of disease spread are explored. Patients with tumours harbouring certain mutations were associated with particular sites of spread. A role for heightened surveillance may be warranted in these patients. The characteristics and mutational profile of patients with multiple melanomas and of patients with clinically atypical melanomas are investigated
Malignant melanoma is a heterogeneous, malignant neoplastic disease, most often originating in the s...
We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protei...
Introduction: Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant m...
Metastasis represents the end product of an elaborate biological process, which is determined by a c...
Melanomas comprise multiple biologically distinct categories, which differ in cell of origin, age of...
Clinicopathological and molecular aspects of cutaneous melanoma. Melanoma arises form the transforma...
Cutaneous malignant melanoma (CMM) is the most lethal form of skin cancer and its incidence has incr...
Introduction: Primary dermal melanoma (PDM) is a recently described clinical entity accounting for l...
Abstract Introduction: Primary dermal melanoma (PDM) is a recently described clinical entity account...
“Cutaneous melanoma is a most unpredictable lesion” wrote Alexander Breslow in 1970. He was one of t...
The characteristics and disease patterns of primary stage I and II cutaneous melanomas that progress...
The characteristics and disease patterns of primary stage I and II cutaneous melanomas that progress...
Melanoma is an aggressive neoplasia issued from the malignant transformation of melanocytes, the pig...
SummaryWe describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and...
Melanoma is a significant cause of morbidity and mortality in Australia. Whilst recent developments ...
Malignant melanoma is a heterogeneous, malignant neoplastic disease, most often originating in the s...
We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protei...
Introduction: Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant m...
Metastasis represents the end product of an elaborate biological process, which is determined by a c...
Melanomas comprise multiple biologically distinct categories, which differ in cell of origin, age of...
Clinicopathological and molecular aspects of cutaneous melanoma. Melanoma arises form the transforma...
Cutaneous malignant melanoma (CMM) is the most lethal form of skin cancer and its incidence has incr...
Introduction: Primary dermal melanoma (PDM) is a recently described clinical entity accounting for l...
Abstract Introduction: Primary dermal melanoma (PDM) is a recently described clinical entity account...
“Cutaneous melanoma is a most unpredictable lesion” wrote Alexander Breslow in 1970. He was one of t...
The characteristics and disease patterns of primary stage I and II cutaneous melanomas that progress...
The characteristics and disease patterns of primary stage I and II cutaneous melanomas that progress...
Melanoma is an aggressive neoplasia issued from the malignant transformation of melanocytes, the pig...
SummaryWe describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and...
Melanoma is a significant cause of morbidity and mortality in Australia. Whilst recent developments ...
Malignant melanoma is a heterogeneous, malignant neoplastic disease, most often originating in the s...
We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protei...
Introduction: Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant m...